Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Profend is a nasal decolonization swab containing a 10% w/w povidone-iodine (PVP-I) solution, equivalent to 1% available iodine. Developed by PDI (Professional Disposables International), it is used preoperatively to reduce the carriage of *Staphylococcus aureus* (including MRSA) and other pathogens in the nares, thereby lowering the risk of surgical site infections (SSIs). Unlike antibiotic treatments such as mupirocin, povidone-iodine acts rapidly—killing 99.7% of *S. aureus* in 60 seconds—and does not contribute to antimicrobial resistance. Its mechanism involves the release of free iodine, which acts as a powerful oxidant that disrupts microbial cell membranes and oxidizes essential proteins and nucleic acids, leading to rapid cell death. The product is designed for ease of use in clinical settings, typically administered within an hour of surgical incision.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Profend.